NLM Digital Collections

Search

Start Over Subjects Antineoplastic Agents -- adverse effects ✖Remove constraint Subjects: Antineoplastic Agents -- adverse effects Dates by Range 2000 and later ✖Remove constraint Dates by Range: 2000 and later

1. Novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects: revised evidence report

Author(s):
Tice, Jeffrey A., author
McKenna, Avery, author
Herce-Hagiwara, Belén, author
Moradi, Ashton, author
Pearson, Steven D., author
Ollendorf, Daniel A., author
Bloudek, Lisa, author
Carlson, Josh J., author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, March 17, 2022
Subject(s):
Antineoplastic Agents -- adverse effects
Chemotherapy-Induced Febrile Neutropenia -- drug therapy
Chemotherapy-Induced Febrile Neutropenia -- prevention & control
Neutropenia -- drug therapy
Neutropenia -- prevention & control
United States

2. Oncology pharmaceuticals: reproductive toxicity testing and labeling recommendations

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, May 2019
Subject(s):
Antineoplastic Agents -- adverse effects
Mutagenicity Tests -- standards
Neoplasms -- drug therapy
Reproduction -- drug effects
Teratogens
Toxicity Tests -- standards
Contraception
Drug-Related Side Effects and Adverse Reactions
Fertility
Geriatrics
Pediatrics
Postmenopause
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.